The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
Personalised proteogenomics has the power to transform the identification, staging and management of NSCLC in never smokers
Two studies add further evidence of the advantages of this route for delivering immune checkpoint inhibitors for patients and healthcare sustainability
Analyses of FLAURA2, MARIPOSA and MARIPOSA-2 trials provide further guidance on treatment choices for advanced lung cancer, but questions remain about optimal sequencing
Efficacy for savolitinib in patients with MET exon 14 alterations is in line with that for other MET tyrosine kinase inhibitors, but safety profile is different
Precision oncology is evolving from advanced to early-stage NSCLC, highlights Prof. Enriqueta Felip in her Heine H. Hansen Award lecture at ELCC 2024
Encouraging EFS and OS results were presented at an ESMO Virtual Plenary for the use of the immune checkpoint inhibitor prior and after surgery
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.